RCT | Lenalidomide-dexamethasone vs. observation in high-risk smoldering myeloma after 12 years of median follow-up time.
8 Sep, 2022 | 14:34h | UTCLenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link to abstract – $ for full-text)